176 related articles for article (PubMed ID: 31015152)
21. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
Nakamura A; Ohwada C; Takeuchi M; Takeda Y; Tsukamoto S; Mimura N; Nagisa OH; Sugita Y; Tanaka H; Wakita H; Aotsuka N; Matsue K; Yokote K; Ohara O; Nakaseko C; Sakaida E
PLoS One; 2019; 14(9):e0221941. PubMed ID: 31483817
[TBL] [Abstract][Full Text] [Related]
22. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
23. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
[TBL] [Abstract][Full Text] [Related]
24. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
25. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients.
Kim SJ; Ryu KJ; Hong M; Ko YH; Kim WS
J Hematol Oncol; 2015 May; 8():49. PubMed ID: 25966773
[TBL] [Abstract][Full Text] [Related]
26. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
27. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
28. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
[TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
Tao Y; Wang S; Wang L; Wu M; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
[No Abstract] [Full Text] [Related]
30. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract][Full Text] [Related]
31. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease.
Han JH; Suh CH; Jung JY; Nam JY; Kwon JE; Yim H; Kim HA
Arthritis Res Ther; 2015 Sep; 17(1):260. PubMed ID: 26385705
[TBL] [Abstract][Full Text] [Related]
32. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
33. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
[TBL] [Abstract][Full Text] [Related]
34. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
35. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
[TBL] [Abstract][Full Text] [Related]
36. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Xu L; Hunter ZR; Tsakmaklis N; Cao Y; Yang G; Chen J; Liu X; Kanan S; Castillo JJ; Tai YT; Zehnder JL; Brown JR; Carrasco RD; Advani R; Sabile JM; Argyropoulos K; Lia Palomba M; Morra E; Trojani A; Greco A; Tedeschi A; Varettoni M; Arcaini L; Munshi NM; Anderson KC; Treon SP
Br J Haematol; 2016 Mar; 172(5):735-44. PubMed ID: 26659815
[TBL] [Abstract][Full Text] [Related]
37. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma.
Li B; Su H; Cao J; Zhang L
Cytokine; 2017 Jan; 89():91-97. PubMed ID: 27663978
[TBL] [Abstract][Full Text] [Related]
38. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
Abeykoon JP; Zanwar S; Ansell SM; Winters J; Gertz MA; King RL; Murray D; Habermann T; Dingli D; Muchtar E; Go RS; Leung N; Inwards DJ; Buadi FK; Dispenzieri A; Lacy MQ; Lin Y; Gonsalves WI; Kourelis T; Witzig TE; Thompson C; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
Am J Hematol; 2018 Nov; 93(11):1384-1393. PubMed ID: 30121949
[TBL] [Abstract][Full Text] [Related]
39. Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
Kyle RA; Benson JT; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Melton LJ; Rajkumar SV
Blood; 2012 May; 119(19):4462-6. PubMed ID: 22451426
[TBL] [Abstract][Full Text] [Related]
40. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
